Long-Term PF-06651600 for the Treatment of Alopecia Areata
NCT04006457
Active Not Recruiting
This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata. Eligible patients from the prior studies B7931005 (NCT02974868) and B7981015 (NCT03732807) will have an opportunity to enroll as well as patients who have not previously participated in either of these studies. The study is open-label and all patients entering the study will receive active study drug... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/21/2025
Locations: Mosaic Dermatology, Beverly Hills, California +5 locations
Conditions: Alopecia Areata
Register for Updates
A Study to Evaluate VXA-CoV2-3.1 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
NCT06672055
Active Not Recruiting
The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.1 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Elligo Health Research (BTC/ClinEdge) - Core Healthcare Group, Cerritos, California +10 locations
Conditions: SARS-CoV2, COVID-19
Register for Updates
Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant
NCT01122784
Completed
Multicenter, randomized, single-blinded comparison of two formulations of the rF1V vaccine at a single dosage of 80 µg and two 3-dose schedules in 400 healthy, adult volunteers in four parallel cohorts. Two rF1V vaccine cohorts (N=160 each) and two rF1V antigen-only cohorts (N=40 each) will be vaccinated at two different three-dose schedules (Days 0, 56 and 182 or Days 0, 56 and 121).
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
07/28/2020
Locations: Benchmark Research, San Francisco, California +1 locations
Conditions: Plague Vaccine
Register for Updates
Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine
NCT01005407
Completed
The purpose of the study is to evaluate the safety, immunogenicity and lot-to-lot consistency of an investigational hepatitis B virus vaccine, HEPLISAV™, in healthy adults 40 to 70 years of age
Gender:
ALL
Ages:
Between 40 years and 70 years
Trial Updated:
03/18/2019
Locations: Not set, San Diego, California +1 locations
Conditions: Healthy
Register for Updates